

# THE ROLE OF **NUTRACEUTICALS** IN DEGENERATIVE DISEASES | PART 2



Editors:  
**Paramita Paul**  
**Ranabir Sahu**  
**Gouranga Nandi**  
**Tarun Kumar Dua**

**Bentham Books**

# **The Role of Nutraceuticals in Degenerative Diseases**

***(Part 2)***

Edited By

**Paramita Paul**

Department of Pharmaceutical Technology  
University of North Bengal, West Bengal  
India

**Ranabir Sahu**

Department of Pharmaceutical Technology  
University of North Bengal, West Bengal  
India

**Gouranga Nandi**

Department of Pharmaceutical Technology  
University of North Bengal, West Bengal  
India

**&**

**Tarun Kumar Dua**

Department of Pharmaceutical Technology  
University of North Bengal, West Bengal  
India

## **The Role of Nutraceuticals in Degenerative Diseases (*Part 2*)**

Editors: Paramita Paul, Ranabir Sahu, Gouranga Nandi & Tarun Kumar Dua

ISBN (Online): 979-8-89881-336-9

ISBN (Print): 979-8-89881-337-6

ISBN (Paperback): 979-8-89881-338-3

© 2026, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore, in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2026.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.org](mailto:permission@benthamscience.org).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

|  |     |
|--|-----|
| <b>FOREWORD</b> .....  | i   |
| <b>PREFACE</b> .....   | iii |
| <b>LIST OF CONTRIBUTORS</b> .....  | v   |
| <b>CHAPTER 1 NUTRACEUTICALS IN THE MANAGEMENT OF CARDIOVASCULAR DISEASES</b> .....         | 1   |
| <i>Esha Das, Piu Jana, Paramita Paul, Ranabir Sahu, Tarun Kumar Dua and Gouranga Nandi</i> |     |
| <b>INTRODUCTION</b> .....  | 2   |
| <b>ARRHYTHMIA</b> .....  | 2   |
| Pathophysiology .....  | 2   |
| <i>Sinus Arrhythmia</i> .....  | 3   |
| <i>Sinus Tachycardia</i> .....   | 3   |
| <i>Sinus Bradycardia</i> .....   | 3   |
| <i>Ectopic Arrhythmia</i> .....  | 3   |
| <i>Supraventricular Tachycardia</i> .....  | 3   |
| <i>Ventricular Dysrhythmia</i> .....   | 4   |
| Management of Arrhythmia by Nutraceuticals .....   | 5   |
| Omega-3 Fatty Acid .....   | 5   |
| Coenzyme Q10 .....   | 5   |
| <i>Dairy Products</i> .....  | 6   |
| <i>Garlic</i> .....  | 7   |
| <i>Vitamin C</i> .....   | 7   |
| <i>Vitamin E</i> .....   | 7   |
| <i>Ginkgo</i> .....  | 7   |
| <b>HYPERTENSION</b> .....  | 7   |
| Pathophysiology .....  | 8   |
| Management of Hypertension by Nutraceuticals .....   | 9   |
| <i>Blueberry and Grapes</i> .....  | 9   |
| <i>Apple</i> .....   | 10  |
| <i>Turmeric</i> .....  | 10  |
| <i>Red wine</i> .....  | 10  |
| <i>Cocoa</i> .....   | 11  |
| <i>Spirulina</i> .....   | 11  |
| <i>Brassica</i> .....  | 11  |
| <i>Barberry</i> .....  | 12  |
| <b>HEART FAILURE</b> .....   | 12  |
| Pathophysiology .....  | 12  |
| Management of Heart Failure by Nutraceuticals .....  | 13  |
| <i>Red Wine, Grapes, and Berries</i> .....   | 13  |
| <i>Quercetin</i> .....   | 13  |
| <i>Cocoa</i> .....   | 13  |
| <i>Turmeric</i> .....  | 14  |
| <i>Barberry</i> .....  | 14  |
| <i>Spirulina</i> .....   | 14  |
| <i>L-arginine</i> .....  | 15  |
| <i>D-ribose</i> .....  | 15  |
| <i>Omega-3 Polyunsaturated Fatty Acids</i> .....   | 15  |
| <i>Coenzyme Q10</i> .....  | 15  |

|   |    |
|---|----|
| <i>Vitamin B1 (Thiamine)</i> .....                          | 16 |
| <i>Vitamin D</i> .....                                      | 16 |
| <i>Vitamin C</i> .....                                      | 16 |
| <b>ATHEROSCLEROSIS</b> .....                                | 17 |
| Pathophysiology .....                                       | 17 |
| Management of Atherosclerosis by Nutraceuticals .....       | 18 |
| <i>Lespedeza</i> .....                                      | 18 |
| <i>Artemisia</i> .....                                      | 18 |
| <i>Omega-3 Fatty Acids</i> .....                            | 18 |
| <i>Nuts</i> .....   | 18 |
| <i>Garlic</i> .....   | 19 |
| <i>Buckwheat</i> .....                                      | 19 |
| <i>Olive Oil</i> .....                                      | 19 |
| <i>Tomato</i> .....   | 19 |
| <i>Pomegranate</i> .....                                    | 20 |
| <i>Mushroom</i> .....                                       | 20 |
| <b>CARDIAC HYPERTROPHY</b> .....                            | 20 |
| Pathophysiology .....                                       | 20 |
| Management of Cardiac Hypertrophy by Nutraceuticals .....   | 22 |
| <i>Turmeric</i> .....                                       | 22 |
| <i>Coenzyme Q10</i> .....                                   | 22 |
| <i>Grapes</i> .....   | 22 |
| <i>Blueberry</i> .....                                      | 23 |
| <i>Barberry</i> .....                                       | 23 |
| <b>ANGINA PECTORIS</b> .....                                | 23 |
| Pathophysiology .....                                       | 23 |
| Management of Angina Pectoris by Nutraceuticals .....       | 24 |
| <i>Coenzyme Q10</i> .....                                   | 24 |
| <i>Hawthorn Plant (Crataegus Monogyna)</i> .....            | 24 |
| <i>Omega-3 Fatty Acid</i> .....                             | 24 |
| <i>Guggul (Commiphora mukul)</i> .....                      | 25 |
| <i>Digitalis</i> .....                                      | 25 |
| <i>Arjuna (Terminalia arjuna)</i> .....                     | 25 |
| <b>MYOCARDIAL INFARCTION</b> .....                          | 25 |
| Pathophysiology .....                                       | 26 |
| Management of Myocardial Infarction by Nutraceuticals ..... | 27 |
| <i>Apples</i> .....   | 27 |
| <i>Grape seed</i> .....                                     | 27 |
| <i>Parsley</i> .....  | 27 |
| <i>Barberry</i> .....                                       | 28 |
| <i>Tea and Coffee</i> .....                                 | 28 |
| <i>Turmeric</i> .....                                       | 28 |
| <i>Polygonum Cuspidatum</i> .....                           | 28 |
| <i>Ginkgo</i> .....   | 29 |
| <i>Red Wine</i> .....                                       | 29 |
| <i>Cocoa</i> .....  | 29 |
| <i>Olives</i> .....   | 29 |
| <i>Vitamin D</i> .....                                      | 30 |
| <i>Vitamin E</i> .....                                      | 30 |
| <i>Vitamin C</i> .....                                      | 30 |
| <i>Spirulina</i> .....                                      | 30 |

|   |    |
|---|----|
| <i>Omega-3 Fatty Acid</i> .....   | 31 |
| <b>HYPERLIPIDEMIA</b> .....   | 31 |
| Pathophysiology .....   | 31 |
| Management of Hyperlipidemia by Nutraceuticals .....                        | 32 |
| <i>Soy proteins</i> .....   | 32 |
| <i>Buckwheat</i> .....  | 32 |
| <i>Marine Proteins</i> .....  | 32 |
| <i>Omega-3 Polyunsaturated Fatty Acid</i> .....                             | 33 |
| <i>Tea</i> .....  | 33 |
| <i>Grape</i> .....  | 33 |
| <i>Wine and Olive Oil</i> .....   | 34 |
| <i>Berberine</i> .....  | 34 |
| <i>Guggul</i> .....   | 34 |
| <i>Fermented Red Rice</i> .....   | 34 |
| <i>Turmeric</i> .....   | 34 |
| <i>Bergamot</i> .....   | 35 |
| <i>Garlic</i> .....   | 35 |
| <b>THROMBOEMBOLISM</b> .....  | 35 |
| Pathophysiology .....   | 36 |
| Management of Thromboembolism by Nutraceuticals .....                       | 36 |
| <i>Natto</i> .....  | 36 |
| <i>Curcumin</i> .....   | 36 |
| <i>Green tea</i> .....  | 37 |
| Contraindication (Nutraceuticals with Cardiovascular Drugs) .....           | 37 |
| <i>Garlic</i> .....   | 37 |
| <i>St. John's Wort</i> .....  | 37 |
| <i>Ginkgo</i> .....   | 37 |
| <i>Green Tea</i> .....  | 38 |
| <i>Red Wine</i> .....   | 38 |
| <i>Olive</i> .....  | 38 |
| <b>CONCLUSION</b> .....   | 38 |
| <b>ACKNOWLEDGEMENTS</b> .....   | 42 |
| <b>REFERENCES</b> .....   | 42 |
| <b>CHAPTER 2 ROLE OF NUTRACEUTICALS IN THE TREATMENT OF ARTHRITIS</b> ..... | 61 |
| <i>Ritu Khanra, Sakshar Saha, Shubham Paul and Atanu Chatterjee</i>         |    |
| <b>INTRODUCTION</b> .....   | 61 |
| <b>PATHOPHYSIOLOGY OF ARTHRITIS</b> .....                                   | 65 |
| <b>BIOMARKERS OF OSTEOARTHRITIS</b> .....                                   | 67 |
| Types of Biomarkers in Osteoarthritis .....                                 | 68 |
| <i>Biochemical Biomarkers</i> .....   | 68 |
| <i>Cartilage Degradation Markers</i> .....                                  | 68 |
| <i>Bone Metabolism Markers</i> .....  | 68 |
| <i>Synovial Inflammation Markers</i> .....                                  | 68 |
| <i>Imaging Biomarkers</i> .....   | 69 |
| <i>Magnetic Resonance Imaging (MRI)</i> .....                               | 69 |
| <i>X-ray</i> .....  | 69 |
| <i>Ultrasound</i> .....   | 69 |
| <i>Genetic Biomarkers</i> .....   | 69 |
| <i>Single Nucleotide Polymorphisms (SNPs)</i> .....                         | 69 |
| <i>Emerging Biomarkers</i> .....  | 70 |

|   |    |
|---|----|
| <i>Metabolomic Biomarkers</i> .....   | 70 |
| <i>Proteomic Biomarkers</i> .....   | 70 |
| Clinical Utility of Biomarkers .....  | 70 |
| <i>Diagnosis</i> .....  | 70 |
| <i>Prognosis</i> .....  | 70 |
| <i>Monitoring Treatment Response</i> .....  | 70 |
| <i>Personalized Medicine</i> .....  | 70 |
| <b>BIOMARKERS OF RHEUMATOID ARTHRITIS</b> .....   | 70 |
| Types of Biomarkers in Rheumatoid Arthritis .....   | 71 |
| <i>Immunological Biomarkers</i> .....   | 71 |
| <i>Rheumatoid Factor (RF)</i> .....   | 71 |
| <i>Anti-Citrullinated Protein Antibodies (ACPAs)</i> .....                                      | 71 |
| <i>Inflammatory Biomarkers</i> .....  | 71 |
| <i>C-Reactive Protein (CRP)</i> .....   | 71 |
| <i>Erythrocyte Sedimentation Rate (ESR)</i> .....   | 72 |
| <i>Interleukin-6 (IL-6)</i> .....   | 72 |
| <i>Genetic Biomarkers</i> .....   | 72 |
| <i>HLA-DRB1</i> .....   | 72 |
| <i>PTPN22</i> .....   | 72 |
| <i>Imaging Biomarkers</i> .....   | 72 |
| <i>Magnetic Resonance Imaging (MRI)</i> .....   | 72 |
| <i>Ultrasound</i> .....   | 72 |
| <i>Emerging Biomarkers</i> .....  | 73 |
| <i>Proteomic Biomarkers</i> .....   | 73 |
| <i>Metabolomic Biomarkers</i> .....   | 73 |
| <b>MARKET VALUE OF THE NUTRACEUTICALS IN ARTHRITIS</b> .....                                    | 73 |
| Comparison of the Nutraceutical Market Size in India to the Global .....                        | 73 |
| <b>NUTRACEUTICALS IN THE MANAGEMENT OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS</b> .....        | 73 |
| Omega-3 Fatty Acid .....  | 75 |
| Vitamin C .....   | 75 |
| Vitamin D .....   | 75 |
| Vitamin E .....   | 76 |
| Polyphenols .....   | 76 |
| Probiotics .....  | 77 |
| <i>Boswellia serrata Extract</i> .....  | 77 |
| Hydrolyzed Collagen .....   | 78 |
| Glucosamine Sulphate and Chondroitin Sulphate .....   | 78 |
| Hyaluronic Acid .....   | 78 |
| Methylsulfonylmethane (MSM) .....   | 78 |
| Shilajit .....  | 78 |
| Bromelain .....   | 78 |
| <b>POTENTIAL SIDE EFFECTS OR INTERACTIONS OF ARTHRITIS MEDICATIONS AND SAFETY PROFILE</b> ..... | 79 |
| <b>REAL-WORLD APPLICATIONS OF NUTRACEUTICALS IN THE TREATMENT OF ARTHRITIS</b> .....            | 80 |
| <b>CONCLUSION</b> .....   | 81 |
| <b>ACKNOWLEDGEMENTS</b> .....   | 82 |
| <b>REFERENCES</b> .....   | 82 |
| <b>CHAPTER 3 BENEFICIAL EFFECT OF NUTRACEUTICALS ON DIABETES MELLITUS</b> .....                 | 85 |

*Sonjit Das, Hiranmoy Bhattacharya, Biplab Debnath and Sanchita Das*

|  |     |
|--|-----|
| <b>INTRODUCTION</b>  | 86  |
| <b>TRADITIONAL NUTRACEUTICALS IN THE MANAGEMENT OF DM</b>                  | 87  |
| Functional Foods   | 88  |
| Carotenoids  | 89  |
| <b>DFS</b>   | 90  |
| Fatty Acids  | 93  |
| Polyphenols  | 94  |
| <i>Flavonoids</i>  | 94  |
| <i>Non-flavonoid Polyphenols</i>   | 98  |
| Probiotics   | 101 |
| <b>NON-TRADITIONAL NUTRACEUTICALS</b>                                      | 104 |
| Fortified Nutraceuticals   | 104 |
| Recombinant Nutraceuticals   | 105 |
| <b>POSSIBLE INTERACTIONS BETWEEN ANTIDIABETIC DRUGS AND NUTRACEUTICALS</b> | 106 |
| <b>CONCLUSION</b>  | 107 |
| <b>REFERENCES</b>  | 107 |

**CHAPTER 4 ROLE OF NUTRACEUTICALS IN THE MANAGEMENT OF DEGENERATIVE OPHTHALMIC DISEASES** ..... 122

*Tapan Kumar Shaw, Moumita Ray, Rania Indu, Abhishek Jana, Dilip Kumar Roy and Kamalakanta Ray*

|   |     |
|---|-----|
| <b>INTRODUCTION</b>   | 123 |
| <b>EYE AND VISION</b>   | 124 |
| <b>VISION DISORDERS</b>   | 125 |
| Degenerative Ophthalmic Diseases  | 126 |
| <i>Glaucoma</i>   | 126 |
| <i>Macular degeneration</i>   | 128 |
| Diabetic Retinopathy  | 129 |
| <i>Retinitis Pigmentosa</i>   | 130 |
| <i>Optic Nerve Disorders</i>  | 130 |
| <b>PATHOGENESIS OF OCULAR DEGENERATIVE DISEASES</b>                             | 131 |
| <b>NUTRACEUTICALS AND OCULAR DISEASES</b>                                       | 133 |
| Nutraceuticals and Ptevention of Degenerative Eye Diseases                      | 136 |
| <b>POTENTIAL SIDE EFFECTS OF NUTRACEUTICALS</b>                                 | 140 |
| <b>DRUG-NUTRACEUTICAL INTERACTION: AN EMERGING CONCERN IN CLINICAL PRACTICE</b> | 141 |
| <b>COST-EFFECTIVE AND INTEGRATIVE APPROACHES OF NUTRACEUTICALS</b>              | 142 |
| <b>CONCLUSION</b>   | 143 |
| <b>ACKNOWLEDGEMENTS</b>   | 144 |
| <b>REFERENCES</b>   | 144 |

**CHAPTER 5 BENEFICIAL EFFECT OF NUTRACEUTICALS ON LIVER DISEASES** ..... 151

*Saurav Sarkar, Prajna Gupta, Gouranga Nandi, Ranabir Sahu, Paramita Paul, Tarun Kumar Dua and Sreejan Manna*

|   |     |
|---|-----|
| <b>INTRODUCTION</b>   | 152 |
| <b>SOURCES AND CHEMISTRY OF SEVERAL NUTRACEUTICALS HAVING BENEFICIAL EFFECTS IN LIVER DISEASES:</b> | 157 |
| Silymarin   | 157 |
| Omega-3 Fatty Acids   | 158 |
| Curcumin  | 158 |

|   |     |
|---|-----|
| Liquorice Root .....  | 159 |
| Vitamin E .....   | 159 |
| Berberine .....   | 159 |
| Ginseng .....   | 160 |
| Beetroot .....  | 160 |
| Probiotics .....  | 161 |
| N-Acetylcysteine (NAC) .....  | 161 |
| <b>COMMONLY OCCURRING LIVER DISEASES</b> .....                                    | 161 |
| Hepatitis .....   | 163 |
| <i>Hepatitis A</i> .....  | 164 |
| <i>Hepatitis B</i> .....  | 165 |
| <i>Hepatitis C</i> .....  | 166 |
| <i>Diagnosis</i> .....  | 166 |
| <i>Hepatitis D Virus</i> .....  | 167 |
| <i>Hepatitis E Virus</i> .....  | 168 |
| Non-alcoholic Fatty Liver Disease (NAFLD) .....                                   | 169 |
| <i>Pathogenesis</i> .....   | 170 |
| <i>Diagnosis</i> .....  | 170 |
| Alcoholic Fatty Liver Disease .....   | 171 |
| <i>Pathogenesis</i> .....   | 171 |
| <i>Diagnosis</i> .....  | 171 |
| Liver Cirrhosis .....   | 172 |
| <i>Pathogenesis</i> .....   | 172 |
| <i>Diagnosis</i> .....  | 173 |
| Hepatocellular Carcinoma .....  | 173 |
| <b>APPLICATIONS OF NUTRACEUTICALS IN LIVER DISEASES</b> .....                     | 174 |
| Hepatitis B .....   | 175 |
| Hepatitis C .....   | 176 |
| NAFLD .....   | 177 |
| Cirrhosis .....   | 180 |
| <b>EFFECT OF NUTRACEUTICALS ON HEPATIC ENZYMES:</b> .....                         | 180 |
| <b>POTENTIAL SIDE EFFECTS OF NUTRACEUTICALS, INTERACTIONS WITH</b>                |     |
| <b>COMMON LIVER MEDICATIONS, AND CONTRAINDICATIONS</b> .....                      | 181 |
| <b>CONCLUSION</b> .....   | 183 |
| <b>ACKNOWLEDGEMENTS</b> .....   | 183 |
| <b>REFERENCES</b> .....   | 183 |
| <b>CHAPTER 6 ROLE OF NUTRACEUTICALS IN THE TREATMENT OF DEGENERATIVE</b>          |     |
| <b>MUSCLE DISEASES</b> .....  | 195 |
| <i>Ranabir Sahu, Ankrita Thapa, Gouhar Jahan Ashraf, Priya Das, Partha Pratim</i> |     |
| <i>Maiti, Paramita Paul, Tarun Kumar Dua and Gouranga Nandi</i>                   |     |
| <b>INTRODUCTION</b> .....   | 196 |
| <b>PATHOPHYSIOLOGY OF DEGENERATIVE MUSCLE DISEASES</b> .....                      | 197 |
| Configuration of Skeletal Muscle and its Function .....                           | 197 |
| <i>Process of Muscle Degeneration</i> .....                                       | 197 |
| <i>Process of Muscle Regeneration</i> .....                                       | 200 |
| Types of Degenerative Muscle Disease .....  | 201 |
| <i>Muscular Dystrophy</i> .....   | 201 |
| <i>Polymyositis</i> .....   | 203 |
| Dermatomyositis .....   | 204 |
| <i>Treatment Options for Dermatomyositis</i> .....                                | 205 |

|   |     |
|---|-----|
| Mitochondrial Myopathies .....  | 205 |
| <i>Treatment</i> .....  | 205 |
| Spinal Muscular Atrophy .....   | 206 |
| <i>Treatment</i> .....  | 206 |
| Nutraceuticals .....  | 206 |
| <b>CONCLUSION</b> .....   | 212 |
| <b>ACKNOWLEDGEMENTS</b> .....   | 212 |
| <b>REFERENCES</b> .....   | 212 |
| <b>CHAPTER 7 ROLE OF NUTRACEUTICALS IN THE TREATMENT OF DEGENERATIVE<br/>OSTEOPOROSIS OR DISC DISEASE</b> ..... | 221 |
| <i>Purnima Ashok, Manasa Deepa R., Uma A. Patil, Bharati Arali, Apoorva Dev,<br/>A. Madhu and Paramita Paul</i> |     |
| <b>INTRODUCTION</b> .....   | 222 |
| Degenerative Disc Disease .....   | 222 |
| Role of Intervertebral Disc Components .....  | 222 |
| Factors Influencing Degenerative Disc Diseases .....  | 223 |
| <b>MECHANISM OF DEGENERATIVE OSTEOPOROSIS/DISC DISEASES</b> .....   | 224 |
| Pathophysiology of Degenerative Osteoporosis .....  | 224 |
| Overview of the Nutrients and Bioactive Compounds with Potential Benefits for Bone<br>Health .....              | 225 |
| Mechanism of Nutraceuticals on DDD .....  | 225 |
| Phytoconstituents .....   | 230 |
| <i>Flavonoids</i> .....   | 231 |
| <i>Polyphenols</i> .....  | 232 |
| <i>Minerals</i> .....   | 233 |
| <i>Vitamins</i> .....   | 233 |
| Glucosamine and Chondroitin .....   | 234 |
| <i>Dairy Products</i> .....   | 234 |
| <i>Prebiotics and Probiotics</i> .....  | 234 |
| <i>Fatty Acids</i> .....  | 234 |
| <i>Melatonin</i> .....  | 234 |
| Essential Nutrients for Bone and Disc Health .....  | 235 |
| Recommended Dietary Guidelines and Supplements to Support Bone Density and Spinal<br>Health .....               | 235 |
| <b>OPTIMIZING NUTRACEUTICAL INTERVENTIONS FOR DDD: FUTURE RESEARCH<br/>DIRECTIONS</b> .....                     | 236 |
| <b>MARKET VALUE OF NUTRACEUTICALS</b> .....   | 237 |
| <b>STRATEGIES TO ENHANCE PATIENT COMPLIANCE WITH NUTRACEUTICAL<br/>REGIMENS</b> .....                           | 238 |
| <b>FUTURE PERSPECTIVES AND CONCLUSION</b> .....   | 239 |
| <b>ACKNOWLEDGEMENTS</b> .....   | 239 |
| <b>REFERENCES</b> .....   | 239 |
| <b>SUBJECT INDEX</b> .....  | 249 |

## FOREWORD

Today's global health landscape is shifting rapidly toward a greater focus on preventative and integrative medicine. This change results from increased incidence rates of chronic degenerative diseases such as cardiovascular diseases, diabetes, arthritis, neurodegenerative diseases, and other similar disorders that continue to place a burden on healthcare systems around the globe, including India's system. The continued rise in the number of incidents will require many novel strategies that extend beyond traditional methods of approaching health care, and will require combining Conventional.

Science with Traditional Practice. Nutraceuticals - compounds that come from nutrient-rich foods - are emerging as valuable partners in health and healing due to their medicinal and therapeutic potentials that are very interesting to the scientific community and that are important in clinical practice, particularly in a country such as India, where the principles of Ayurveda and the traditional dietary culture are inseparable from food and medicine. The book, *The Role of Nutraceuticals in Degenerative Diseases*, is timely and extensive in its coverage of these topics. It takes a critical view regarding the potential for natural compounds to slow the progression of disease and alleviate suffering from Debilitating conditions. The editors of this volume have chosen the chapters that address a wide variety of disease States and present a Comprehensive and Evidence-Based approach that is a merger between Modern Nutritional Science and Ancient Traditions.

This book provides readers with information about the most common therapeutics that can improve our health and quality of life across different categories of nutraceutical use. The categories are:

1. Cardiovascular Disease- The natural compounds found in many of the products marketed as cardiovascular health support can improve heart health and well-being.
2. Arthritis and Osteoporosis- Nutritional strategies to reduce joint and bone degeneration will assist individuals suffering from these chronic illnesses.
3. Diabetes- Nutraceuticals, specifically as it pertains to glycemic control and chronic diabetes complications' prevention, will improve glycemic management.
4. Ophthalmic Disorders- These types of disorders are often overlooked, but they also represent a growing problem in our society and the health industry.
5. Liver Disorders- Again, these types of disorders are often overlooked, but they also represent a growing problem.
6. Muscle Wasting- The role of nutrition interventions to improve muscle disease management needs further study.

Each chapter contains an enormous amount of information on the mechanisms of action, clinical evidence, and practical applications of each of the products discussed in this book, which makes this book an essential resource for all researchers, clinicians, pharmacists, nutritionists, and students.

This book's editors and contributors deserve credit for producing such an authoritative information source and successfully bridging the divide between traditional Indian medicine's

perspective of food as medicine and traditional science.

Therefore, the book "The Role of Nutraceuticals in Degenerative Diseases" is a true addition to the scientific community and will undoubtedly become a guide for healthcare providers who strive to deliver better care and improve the quality of life as the number of individuals suffering from chronic illness increases.

**Bhaskar Mazumder**  
Department of Pharmaceutical Sciences  
Dibrugarh University  
Assam-786004  
India

## PREFACE

The terms "nutrition" and "pharmaceutical" were combined to form the phrase "nutraceutical," which was coined by Dr. Stephen De Felice in 1989. These are foods, or portions of foods, that offer a variety of health advantages, such as disease prevention and/or treatment. Nutraceuticals have numerous benefits, including beneficial results in the prevention and management of complex diseases. Nutraceuticals are beneficial in various therapeutic areas, but their administration and prescription are necessary, and they should be adequately monitored to prevent uncontrolled use and adverse effects. A degenerative disease is a condition where cells, tissues, and organs gradually and irreversibly deteriorate. Over time, this deterioration can cause cell death, impairment, or loss of function. Degenerative diseases are placing a growing economic and social burden on societies, particularly as the world's population increases. Nutraceuticals offer an alternative approach to treating degenerative diseases. In our first volume, we have covered the general introduction to nutraceuticals, degenerative diseases, and potential nutraceuticals based on *in silico* studies. The first volume also explores the role of nutraceuticals in treating degenerative diseases of the respiratory tract, neurodegenerative diseases, and degenerative kidney diseases.

The second volume of this book, "The Role of Nutraceuticals in Degenerative Diseases," is a collection of seven chapters that offer scientific information on the significance of nutraceuticals and their potential roles in the management, treatment, and prevention of degenerative diseases, including arthritis, diabetes, cardiovascular diseases, degenerative ophthalmic disease, muscle disease, liver disease, and degenerative osteoporosis. We believe the nutraceutical industry is moving in the right direction. The selected chapters are easily comprehensible and well-illustrated. A broad audience, particularly food scientists, engineers, biotechnologists, biochemists, and industrial companies, as well as any reader interested in learning more about the role of Nutraceuticals in the management of degenerative diseases.

We are grateful to all the authors for their contributions to the completion of this book. We sincerely hope you liked this book, and we'd love to hear your ideas and suggestions for future versions.

**Paramita Paul**

Department of Pharmaceutical Technology  
University of North Bengal, West Bengal  
India

**Ranabir Sahu**

Department of Pharmaceutical Technology  
University of North Bengal, West Bengal  
India

**Gouranga Nandi**

Department of Pharmaceutical Technology  
University of North Bengal, West Bengal  
India

**&**

**Tarun Kumar Dua**

Department of Pharmaceutical Technology  
University of North Bengal, West Bengal  
India

## List of Contributors

|                              |   |
|------------------------------|---|
| <b>Atanu Chatterjee</b>      | Department of Pharmaceutical Technology, Bengal School of Technology, Hooghly, West Bengal, India   |
| <b>Abhishek Jana</b>         | JIS Institute of Pharmacy, Kalyani, India   |
| <b>Ankrita Thapa</b>         | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India   |
| <b>Apoorva Dev</b>           | East West College of Pharmacy, East West College of Pharmacy, Bengaluru-560091, India   |
| <b>A. Madhu</b>              | East West College of Pharmacy, East West College of Pharmacy, Bengaluru-560091, India   |
| <b>Biplab Debnath</b>        | Bharat Technology, Bharat Technology, Howrah-711316, West Bengal, India   |
| <b>Bharati Arali</b>         | East West College of Pharmacy, East West College of Pharmacy, Bengaluru-560091, India   |
| <b>Dilip Kumar Roy</b>       | Department of Pharmaceutical Technology, JIS University, Kolkata, India   |
| <b>Esha Das</b>              | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India   |
| <b>Gouranga Nandi</b>        | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India   |
| <b>Gouhar Jahan Ashraf</b>   | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India   |
| <b>Hiranmoy Bhattacharya</b> | Bharat Technology, Bharat Technology, Howrah-711316, West Bengal, India   |
| <b>Kamalakanta Ray</b>       | Department of Pharmaceutical Technology, JIS University, Kolkata, India   |
| <b>Moumita Ray</b>           | Department of Pharmaceutical Technology, JIS University, Kolkata, India   |
| <b>Manasa Deepa R.</b>       | East West College of Pharmacy, East West College of Pharmacy, Bengaluru-560091, India   |
| <b>Piu Jana</b>              | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India   |
| <b>Paramita Paul</b>         | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India   |
| <b>Prajna Gupta</b>          | BCDA College of Pharmacy & Technology, Kolkata, India   |
| <b>Priya Das</b>             | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India<br>Department of Pharmaceutical Technology, Brainware University, Barasat, Kolkata, India |
| <b>Partha Pratim Maiti</b>   | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India   |
| <b>Purnima Ashok</b>         | East West College of Pharmacy, East West College of Pharmacy, Bengaluru-560091, India   |
| <b>Ranabir Sahu</b>          | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India   |

|                         |   |
|-------------------------|---|
| <b>Ritu Khanra</b>      | Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata-700109, West Bengal, India   |
| <b>Rania Indu</b>       | Department of Pharmaceutical Technology, JIS University, Kolkata, India   |
| <b>Sakshar Saha</b>     | Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata-700109, West Bengal, India   |
| <b>Shubham Paul</b>     | Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata-700109, West Bengal, India   |
| <b>Sonjit Das</b>       | Regional Institute of Paramedical and Nursing Sciences, Regional Institute of Paramedical and Nursing Sciences, Aizawl-796017, Mizoram, India |
| <b>Sanchita Das</b>     | Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata-700109, India  |
| <b>Saurav Sarkar</b>    | Department of Pharmaceutical Technology, University of North Bengal, Darjeeling, India  |
| <b>Sreejan Manna</b>    | Department of Pharmaceutical Technology, Brainware University, Barasat, India   |
| <b>Tarun Kumar Dua</b>  | Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India   |
| <b>Tapan Kumar Shaw</b> | Department of Pharmaceutical Technology, JIS University, Kolkata, India   |
| <b>Uma A. Patil</b>     | East West College of Pharmacy, East West College of Pharmacy, Bengaluru-560091, India   |

## CHAPTER 1

# Nutraceuticals in the Management of Cardiovascular Diseases

**Esha Das<sup>1,#</sup>, Piu Jana<sup>1,#</sup>, Paramita Paul<sup>1</sup>, Ranabir Sahu<sup>1</sup>, Tarun Kumar Dua<sup>1</sup> and Gouranga Nandi<sup>1,\*</sup>**

<sup>1</sup> *Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India*

**Abstract:** Nutraceuticals are natural food-derived components that provide additional health benefits and potentially reduce cardiovascular disease (CVD) risk factors, such as hypertension, arrhythmia, myocardial infarction, hypertrophy, and atherosclerosis.

The objective of this book chapter is to explore the underlying mechanisms and provide a thorough assessment of the effects and benefits of nutraceuticals, such as garlic, grapes, ginger, turmeric, onion, blueberry, apple, brassica, tulsi, papaya, spirulina, etc.

Dietary habits have an immense effect on cardiovascular health. It has been established that nutraceuticals target various pathways involved in the evolution of CVD and offer a comprehensive approach for treating and preventing CVD. Studies show that consumption of nutraceuticals, such as omega-3 fatty acids, garlic, and dietary fibres in the diet, can improve cardiovascular risk factors, such as hypertension and hyperlipidemia, by reducing blood pressure and lipid profile levels. More specifically, it has been demonstrated that nutraceuticals like grapes, turmeric, and omega-3 fatty acids exhibit anti-inflammatory and anti-oxidation characteristics vital for healthy human blood vessels and arteries. However, these promising results have been achieved through heterogeneous study designs and therefore require further research regarding the applications of nutraceuticals in clinical practice.

In conclusion, nutraceuticals show an attractive emerging field in treating CVD. When combined with traditional therapies, nutraceuticals can play a supportive role by mitigating risk factors while improving treatment outcomes, thereby serving as an essential component of extensive cardiovascular treatment. Future research is needed to better understand the effects and potential of nutraceuticals in improving cardiovascular health.

**Keywords:** Atherosclerosis, Hypertension, Myocardial infarction, Nutraceuticals, Spirulina, Turmeric.

\* **Corresponding author Gouranga Nandi:** Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India; E-mail: nandi\_gouranga@yahoo.co.in

# These authors contributed equally

## INTRODUCTION

Cardiovascular disease (CVD) is one of the most prevalent health problems and is responsible for approximately 17.3 million deaths globally [1]. Many kinds of risk factors associated with CVD are either preventable or manageable. These include obesity, hypertension, high cholesterol, diabetes, metabolic syndrome, smoking, poor diet, and sedentary lifestyle [1, 2]. Nutraceuticals are substances derived from dietary sources that contain bioactive components of natural origin, prevent or manage several diseases, and thus provide potential health benefits. The term “nutraceutical” was coined by S. DeFelice in the early 1980s. Dietary habits vary widely between regions and countries, affecting CVD's prevalence. Improving diet quality could potentially reduce this disease burden. In recent years, people have generally opted for nutraceuticals over synthetic pharmaceuticals because of fewer adverse effects, a lower risk of overdose, minimal chemical alteration, and more holistic benefits. Over the past decade, there has been a rapid increase in the development and availability of nutraceutical products to meet the growing demand for health management remedies [3].

The impact of nutraceuticals on CVD risk is reviewed in this chapter based on the most recent research. A lot of attention is drawn to nutraceuticals such as spirulina, resveratrol, chocolate, quercetin, curcumin, brassica vegetables, berberine, and their roles, as well as the clinical study data that is currently available to support their potential benefits in boosting cardiovascular health.

## ARRHYTHMIA

An arrhythmia occurs when a regular rhythmic cycle in the heartbeat is interrupted. This problem can result from irregularities of the electrical signal in the heart, premature contraction, or obstruction in the conduction pathway. Any disruption in the continuous transmission of electrical impulses that control the heartbeat can lead to arrhythmia. Medically, a rapid heart rhythm is termed tachycardia ( $>100$  beats/min) and a slow heart rhythm is termed bradycardia ( $<60$  beats/min), where a normal sinus rhythm is 72 beats/min [4 - 6].

### Pathophysiology

The heart comprises modified neuromuscular cells, including the sinoatrial (SA) node and atrioventricular (AV) node. The SA is the heart's primary pacemaker, generating electrical impulses that are transmitted to all atria through depolarization. The AV node delays the generation rate for 0.1 seconds, filling the ventricle with blood. From the AV node, the impulses travel to the Bundle of His and then to the Purkinje fibres, eventually spreading all over the ventricles. This initiates ventricle contraction. Blood reaches the aorta and pulmonary artery,

ensuring normal heart rhythm. When the SA node acts as a pacemaker, the different types of arrhythmias happen [4, 6, 7]. Some types of arrhythmias are described below:

### ***Sinus Arrhythmia***

Respiratory sinus arrhythmia occurs due to variations in impulse transmission through the SA node. During inspiration, intrathoracic pressure decreases, increasing lung volume and venous return. It stimulates stretch receptors, which in turn cause the brain to receive vagal afferent impulses. This raises the heart rate, reduces vagal tone, and contracts the vasodilated portion. Expiration increases intrathoracic and lung pressure, causing lung volume reductions and dilation of the vasodilator area, resulting in a decreased heart rate. The electrocardiogram (ECG) shows a moderate heart rate during expiration and a high heart rate during inspiration [6].

### ***Sinus Tachycardia***

Abnormal heart rate increases due to SA node stimulation, leading to depolarization and increased heart rate. This leads to decreased cardiac output and angina-like pain, with decreased R-R interval in the ECG [6, 8].

### ***Sinus Bradycardia***

Sinus bradycardia is characterized by a heart rate less than 60 beats/min and proper cardiac muscle depolarization that starts at the sinus node. Most patients are asymptomatic, but some may have headaches, dizziness, fatigue, weakness, shortness of breath, chest pain, and low Blood Pressure (BP) [6, 9].

### ***Ectopic Arrhythmia***

An irregular heartbeat that results from an electrical impulse coming from an unusual place inside the heart, instead of the heart's typical pacemaker, is known as an ectopic arrhythmia. Sometimes, a few people don't experience any symptoms, but when it occurs, people may feel a fluttering sensation in the chest, palpitation, a missed heartbeat, *etc.*

### ***Supraventricular Tachycardia***

When the atrial muscles and AV node function as pacemakers, they generate impulses, trigger an unexpected attack, and result in tachycardia [10].

## CHAPTER 2

# Role of Nutraceuticals in the Treatment of Arthritis

**Ritu Khanra<sup>1,\*</sup>, Sakshar Saha<sup>1</sup>, Shubham Paul<sup>1</sup> and Atanu Chatterjee<sup>2</sup>**

<sup>1</sup> *Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata-700109, West Bengal, India*

<sup>2</sup> *Department of Pharmaceutical Technology, Bengal School of Technology, Hooghly, West Bengal, India*

**Abstract:** Arthritis refers to joint pain, inflammation, or joint disease. It is the most common cause of disability, affecting people of all ages, races, and genders. In most cases, women are more commonly affected, and symptoms may worsen over time. Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammatory arthritis and extra-articular involvement. It typically starts in small peripheral joints, is usually symmetric, and may progress to involve proximal joints if left untreated. Joint inflammation over time can lead to the destruction of the joint, resulting in loss of cartilage and bone erosion. Osteoarthritis (OA) is a chronic autoimmune disease that primarily targets the lining of synovial joints, leading to progressive disability, early mortality, and socioeconomic challenges. The pathogenesis of OA presents a multifaceted landscape, involving diverse etiologies and intricate molecular and cellular mechanisms. OA manifests as functional impairment of the joint, characterized by alterations in joint morphology resulting from the erosion of articular cartilage, the formation of osteophytes, subchondral sclerosis, bone marrow lesions (BMLs), and synovial proliferation. The role of chondroitin sulfate (CS) biosynthesis in OA is highlighted, with altered CS chain length correlating with disease severity. Nutraceuticals have been shown to be effective in the management of both OA and RA by acting as anti-inflammatory agents, primarily through the inhibition of the tumor necrosis factor (TNF) catabolic signaling pathway in chondrocytes. In this chapter, we discuss the effectiveness, safety, and toxicity of nutraceutical products in the treatment of RA and OA.

**Keywords:** Arthritis, Nutraceuticals, Osteoarthritis, Rheumatoid arthritis.


## INTRODUCTION

There are over 100 different types of arthritis and associated disorders. The term “arthritis” refers to joint pain, inflammation, or disease of the joints. The most

---

\* **Corresponding author Ritu Khanra:** Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata-700109, West Bengal, India; E-mails: [ritu.khanra@jisuniversity.ac.in](mailto:ritu.khanra@jisuniversity.ac.in); [rituju2012@gmail.com](mailto:rituju2012@gmail.com)

common cause of disability, arthritis, affects people of all ages, races, and genders. The majority of cases occur in women, and while arthritis is not solely age-related, some forms tend to worsen with age. According to the World Health Organisation (WHO), osteoarthritis affected 528 million individuals globally in 2019, representing a 113% increase from 1990. Furthermore, 60% of those with osteoarthritis are women, and about 73% of affected individuals are older than 55 (Fig. 1).



**Fig. (1).** Prevalence of osteoarthritis (OA) for both sexes combined in 204 countries and territories. **A:** Age-standardized prevalence rate (ASR) of OA in 2019. **B:** Percentage change in prevalent cases of OA between 1990 and 2019. **C:** Estimated annual percentage change (EAPC) of OA from 1990 to 2019 [1].

On the other hand, 18 million people worldwide suffered from rheumatoid arthritis in 2019, as per the WHO (Fig. 2). Hence, approximately 550 million people are affected by various types of arthritis. The knee is the most commonly affected joint, followed by the hip and the hand [1]. The most common form of arthritis is osteoarthritis (OA). The symptoms of arthritis include pain, swelling, reduced range of motion, and stiffness. In osteoarthritis, an inflammatory joint disease, the main features include subchondral sclerosis, osteophyte formation, alterations in the synovial membrane, and bone enlargement at the joint margins. In contrast, rheumatoid arthritis is characterized by bone loss and synovial inflammation. In both conditions, cartilage may gradually lose its flexibility, eventually wearing down to the point where bone scrapes against bone. In severe cases, cartilage fragments may break off, resulting in intense pain in the muscles adjacent to the affected bone. The progression of these morphological and biochemical changes leads to gradual joint deterioration, reduced mobility and stability, deformity, pain, stiffness, and loss of function. Arthritis is diagnosed through physical examination, radiographic, and microradiographic data. Magnetic resonance imaging (MRI) can reveal joint abnormalities and cartilage degradation, particularly in osteoarthritis [2].

Currently, arthritis has no known cure. The primary goal of treatment is to reduce symptoms such as pain and inflammation while maintaining joint mobility. To achieve this, a variety of pharmaceuticals, nutraceuticals, disease-specific therapies, stem cell treatments, and physiotherapy may be employed. To overcome pain and inflammation, cyclooxygenase (COX)-inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs) have been most commonly used to manage OA. Unfortunately, long-term use of NSAIDs has several adverse effects, such as reduced appetite, vomiting, ulcers, and hepatic as well as renal dysfunction. The American Journal of Medicine revealed in 1998 that NSAIDs resulted in over 100,000 hospital admissions and 16,000 arthritis-related deaths annually in the US.

Alternative treatments for arthritis include weight loss, balanced diet, nutraceuticals, and natural herbs. Nutraceuticals with anti-inflammatory and anti-arthritic properties have gained popularity recently. Nutraceuticals have recently gained popularity as “self-help” treatments among arthritis patients. These include glucosamine, chondroitin, type II collagen, shilajit, 5-Loxin, avocado/soybean unsaponifiables, curcumin, and many others. The effectiveness, safety, and toxicity of nutraceuticals in OA are briefly discussed in this chapter.

## CHAPTER 3

# Beneficial Effect of Nutraceuticals on Diabetes Mellitus

**Sonjit Das<sup>1</sup>, Hiranmoy Bhattacharya<sup>2</sup>, Biplab Debnath<sup>2</sup> and Sanchita Das<sup>3,\*</sup>**

<sup>1</sup> *Regional Institute of Paramedical and Nursing Sciences, Aizawl-796017, Mizoram, India*

<sup>2</sup> *Bharat Technology, Howrah-711316, West Bengal, India*

<sup>3</sup> *Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata-700109, India*

**Abstract:** In recent years, emerging evidence suggests that nutraceuticals, due to their variety and multifaceted therapeutic impacts, may be a distinct and complementary prophylactic option for diabetes and its complications. Several nutraceuticals, including vitamin C,  $\alpha$ -lipoic acid, L-carnitine, co-enzyme Q10, and others, have shown anti-diabetic properties over the years. In this chapter, we look at the possible benefits of nutraceuticals against this metabolic disorder and relevant complications. According to several pre-clinical and clinical studies, nutraceuticals can alter the metabolism of lipids and carbohydrates, induce hypoglycaemic effects, reduce insulin resistance and dyslipidaemia, improve lipolysis in adipose tissues, reduce free radical damage, stress-sensitive cascades, and mitigate inflammatory responses. Nutraceuticals can also help in the prevention of chronic diabetic consequences, including cardiovascular complications, nephropathy, CNS ailments, and retinopathy. In summary, the role of nutraceuticals in diabetes treatment is rapidly expanding, with a wide range of bioactive compounds supporting diabetic care through multiple pathways. The advantages of these products include better glycaemic control, enhanced insulin sensitivity, and fewer complications from diabetes. Nutraceuticals are expected to become more significant in the treatment of diabetes as scientific knowledge advances. They offer a holistic approach that empowers people through lifestyle modifications aimed at enhancing long-term health outcomes in addition to supplemental medication therapy. Further research, focusing on clinical utilization, is required to determine nutraceutical supplementation in diabetic patients.

**Keywords:** Carbohydrates, Diabetes, Hyperglycaemia, Insulin resistance, Nutraceuticals.

---

\* **Corresponding author Sanchita Das:** Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata- 700109, India; E-mail: sanchita.das@jisuniversity.ac.in

## INTRODUCTION


Diabetes mellitus (DM), a chronic lifestyle-related disorder, is characterized by an abnormally raised blood glucose level. This induction of hyperglycaemia can occur owing to impaired insulin production and/or resistance to the peripheral activity of insulin in insulin-sensitive tissues [1]. Different types of diabetes include type 1 DM (T1DM), type 2 DM (T2DM), gestational diabetes (GDM), and additional specific, less-frequent variants, where T2DM is the most commonly occurring type of diabetes [2].

In developing countries, the number of DM patients is growing at a concerning rate, primarily driven by the escalating prevalence of obesity throughout the lifespan, largely attributed to laziness and poor eating habits. According to Saeedi and colleagues, the global occurrence of diabetes is projected to reach 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [3]. Among the continents, Europe has the highest number of T2DM patients [1]. The trend of the prevalence of diabetes underscores the urgent need for effective public health interventions to address lifestyle factors contributing to DM [1].

In T1DM, insulin-producing pancreatic  $\beta$  cells are destroyed, leading to elevated serum glucose levels [4]. Type 2 diabetes mellitus (T2DM) is caused by decreased sensitivity to insulin. In advanced stages of T2DM, a reduction in  $\beta$ -cell mass and function occurs, along with impaired insulin signaling. This progression is also accompanied by altered lipid metabolism and low-grade, chronic inflammation, resulting in tissue damage, fostering diabetes-related complications [5]. Other complications associated with diabetes include angiopathy [6], high blood pressure [7], nephropathy [8, 9], retinopathy [10], neuropathy [11], foot ulcers [12], and weight gain (Fig. 1) [13]. Oral antidiabetic medications used to address diabetic complications are grouped into sulfonylureas, thiazolidinediones, meglitinides, sodium-glucose co-transporter (SGLT2) inhibitors,  $\alpha$ -glucosidase antagonists, dipeptidyl peptidase-4 (DPP4) blockers, biguanides, and incretin-like compounds [14]. Presently available contemporary anti-diabetic medications are mostly synthetic in nature, often accompanied by high costs and a range of potential side effects [5].

Nature-derived products have significantly contributed to the development of novel classes of hypoglycemic agents [5]. Nutraceuticals, primarily derived from naturally occurring foods, possess the potential to prevent various pathological conditions. DM is one of the most commonly occurring lifestyle-related ailments that can be mitigated through different mechanisms with nature-derived nutraceutical products [15]. According to Mabena and co-workers, nutraceuticals are broadly categorized into traditional and non-traditional types [15]. The anti-

diabetic potential of various nutraceuticals, such as vitamin C,  $\alpha$ -lipoic acid (ALA), L-carnitine, and coenzyme Q10, has been revealed over the years [16]. Nutraceuticals act through various processes including the activation of nuclear factor erythroid 2-related factor 2 (Nrf2), promoting the transcription of glyoxalase I, inducing mitophagy as well as mitochondrial biogenesis, boosting uncoupling protein 2, inhibiting NADPH oxidase, recoupling endothelial nitric oxide synthase (eNOS), providing glutathione (GSH) precursors, scavenging membrane oxidants, correcting thiamine deficiency to quell oxidative stress and dicarbonyl stress, thus potentially preventing diabetic complications [17]. In this chapter, various classes of nutraceuticals will be discussed, along with insights into their antidiabetic activity.



**Fig. (1).** Various complications related to diabetes.

## TRADITIONAL NUTRACEUTICALS IN THE MANAGEMENT OF DM

Nutraceuticals obtained from natural sources and used to deliver beneficial roles in human health over time are known as traditional nutraceuticals. These

## CHAPTER 4

## Role of Nutraceuticals in the Management of Degenerative Ophthalmic Diseases

Tapan Kumar Shaw<sup>1,\*</sup>, Moumita Ray<sup>1</sup>, Rania Indu<sup>1</sup>, Abhishek Jana<sup>2</sup>, Dilip Kumar Roy<sup>1</sup> and Kamalakanta Ray<sup>1</sup>

<sup>1</sup> Department of Pharmaceutical Technology, JIS University, Kolkata, India

<sup>2</sup> JIS Institute of Pharmacy, Kalyani, West Bengal, India

**Abstract:** Nutraceuticals, derived from food sources, offer additional health benefits beyond basic nutrition. Combining “nutrient” and “pharmaceutical,” nutraceuticals are increasingly recognized for their potential in managing various diseases, particularly ocular disorders, without the side effects often associated with synthetic pharmaceuticals. These natural compounds contribute to vital biological processes, including antioxidant defence and cellular integrity, thereby enhancing health, preventing chronic diseases, and potentially extending life expectancy. With various forms available, such as pills, powders *etc.*, nutraceuticals are easily accessible and cost-effective. In the realm of neurodegenerative diseases, nutraceuticals can play a significant role in mitigating conditions affecting vision, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma. These disorders are often linked to oxidative stress, wherein reactive oxygen species (ROS) contribute to retinal ganglion cell degeneration. Nutraceuticals with antioxidant properties have been shown to reduce ROS levels, thereby offering a protective effect against ocular degeneration. This chapter briefly focuses on the pathophysiology of common degenerative eye diseases and discusses the potential of nutraceuticals in their prevention and management. By enhancing nutritional intake without altering physiological states, nutraceuticals present a compelling alternative to conventional drugs, particularly for age-related vision disorders, promoting overall ocular health and potentially reducing the prevalence of vision impairment in aging populations.

**Keywords:** Degenerative diseases, Management, Nutraceuticals, Ophthalmic diseases, Pathophysiology.

---

\* Corresponding author Tapan Kumar Shaw: Department of Pharmaceutical Technology, JIS University, Kolkata, India; E-mail: tapan2009@gmail.com

## INTRODUCTION

A nutraceutical is any product made from food sources that offers additional health advantages beyond the fundamental nutritional value of food. Combining the terms “nutrient,” which describes a healthy food item, and “pharmaceutical,” which describes a medical therapy, result in the term “nutraceutical.” Thus, novel materials in the health sciences may offer a new way to treat different disorders and these are also essential for running the life for a healthy human life.

So, nutraceuticals can have potential roles in the management of many diseases, including eye diseases [1, 2]. Nutraceuticals have garnered much attention in recent years because of their possible benefits in terms of safety and therapy, unlike pharmaceuticals like drug formulations. The drug formulations contain mostly synthetic chemicals, both therapeutic agents (drugs) and auxiliary chemicals (excipients), which may produce side effects or toxicities [3, 4]. Nutraceuticals are beneficial in the management of diseases as they differ from pharmaceuticals in their natural quality. They do not alter any normal physiological condition in our body; rather, they complement the diet with more nutritious values [5].

Nutraceuticals play a crucial role in numerous biological processes, including antioxidant defence, cell proliferation, gene expression, and maintaining mitochondrial integrity, which may be impacted by these products. Nutraceuticals can, therefore, be used to maintain the integrity and functioning of the body as well as enhance health, prevent chronic diseases, delay the aging process, and ultimately lengthen life expectancy. Nutraceuticals like pharmaceuticals are also available in different dosage forms, such as pills, capsules, tablets, powders, *etc.*, which resemble pharmaceuticals. They are easily prepared, easy to apply, and provide extensive functionality in humans [6 - 8]. Nutraceuticals are available in various forms in the market based upon their chemical nature, like lipid, protein, carbohydrate, micronutrient; mechanism of action, like metabolic impact, physiologic impact [9 - 11]. Nutraceuticals have a versatile impact on our body, such as an immune system boost by vitamin A, vitamin C [12, 13]; anti-inflammatory properties by carotenoids [14, 15]; cardiovascular system boost by fatty acids [16, 17]; and neurological disorder protectant by phytochemicals [18]. Apart from all these, nutraceuticals have limited side effects, which attracts more people to them as pharmaceutical alternatives [18, 19]. Patient compliance is much higher for nutraceuticals than for pharmaceuticals, also due to their 100% biocompatibility.

Most importantly, nutraceuticals do not change any physiological condition; rather, they work as food supplements to provide important nutrition to our body.

Also, nutraceuticals are easy to manufacture from low cost natural raw materials and cheaply available for people [20]. Another vital point is due to its non-prescription selling practice, people often purchase them for their health benefits, indicating the higher accessibility of nutraceuticals [21].

The progressive degeneration and eventual death of nerve cells in the brain or the peripheral nervous system are the cause of neurodegenerative diseases. Alzheimer's disease and Parkinson's disease are the most well-known, pervasive, and prevalent degenerative disorders among the aged population. However, neurodegenerative processes affect both the retina and the central nervous system (CNS). Amongst the neurodegenerative diseases particularly affecting the normal health of the eye, age-related macular degeneration (AMD), diabetic retinopathy (DR), cataracts, dry eye disease (DED), glaucoma, and presbyopia are commonly prevalent [22]. The primary mechanism underlying retrograde (presynaptic neurons) and anterograde (postsynaptic neurons) trans-synaptic neurodegeneration is the death of retinal ganglion cells. Oxidative stress plays a major pathophysiological role in the ocular degenerative diseases. It has been demonstrated that reactive oxygen species (ROS), whether from internal or external sources, are essential for the survival of ocular tissues [23]. To reduce ROS generation, various nutraceuticals with antioxidant properties have been reported to be beneficial in preventing ocular degenerative diseases [24]. In this chapter, the pathophysiology of the different degenerative ophthalmic diseases is focused on, with the possible nutraceuticals and their role in preventing the occurrence of these ophthalmic diseases.

## EYE AND VISION

The eye is an extraordinary organ that captures and focuses light, converting it into chemical and electrical signals sent to the brain, where they are interpreted as visual images. It comprises the body's only two clear tissues; one is directly involved in vision, include the cornea and lens, which focus light onto the retina's central foveal area (macula). The retina then transforms the light into signals transmitted *via* the optic nerve to the brain. Supporting tissues, like the aqueous humor, nourish the lens. The retina and brain together form the CNS, which is responsible for our sense of sight [25]. The eye uses a focusing lens to project an inverted image onto a dense array of light-sensitive receptors, which convert light patterns into electrical impulses that the brain can interpret. Vision begins in the retinas, which are brain outgrowths containing rods and cones; rods detect shades of gray in low light, while cones detect color in daylight. There is no color vision at the borders of the retina because there are few cones there. Images from the right half of each retina are processed on the left side of the brain, and *vice versa*, because the optic nerve fibers from the inner and outer halves of the retinas cross

## CHAPTER 5

# Beneficial Effect of Nutraceuticals on Liver Diseases

Saurav Sarkar<sup>1</sup>, Prajna Gupta<sup>1,2</sup>, Gouranga Nandi<sup>1</sup>, Ranabir Sahu<sup>1</sup>, Paramita Paul<sup>1</sup>, Tarun Kumar Dua<sup>1</sup> and Sreejan Manna<sup>1,3,\*</sup>

<sup>1</sup> Department of Pharmaceutical Technology, University of North Bengal, Darjeeling, West Bengal-734013, India

<sup>2</sup> BCDA College of Pharmacy & Technology, Kolkata-700127, India

<sup>3</sup> Department of Pharmaceutical Technology, Brainware University, Barasat, Kolkata, West Bengal-700125, India

**Abstract:** Nutraceuticals are employed to improve health, offering physiological benefits alongside their nutritional value. Nutraceuticals can support the normal functioning of the human body, prevent certain diseases, and slow down the aging process. The edible nature, absence of adverse effects, and excellent *in vivo* compatibility have made nutraceuticals an excellent alternative to available marketed dosage forms. Recently, liver disorders have emerged as one of the major issues due to an unhealthy lifestyle. The over-consumption of medicines can also affect the healthy liver. Nutraceuticals can be an alternative and effective option for preventing and managing liver diseases. Several nutraceuticals are reported to be effective against different liver disorders, including hepatitis, non-alcoholic fatty liver disease, alcoholic fatty liver disease, liver cirrhosis, hepatocellular carcinoma, *etc.* The most commonly applied nutraceuticals in the treatment of several liver disorders include silymarin, Omega-3 fatty acids, curcumin, liquorice root, vitamin E, berberine, ginseng, beetroot, and probiotics. These nutraceuticals have shown considerable efficacy in the therapy of various liver diseases. The beneficial effects of nutraceuticals can surely encourage their use in the prevention and therapy of hepatic disorders. However, further randomized controlled studies are required to establish the direct effect of nutraceuticals on liver diseases with histological changes. This chapter provides a detailed insight into various liver disorders, including their pathogenesis and diagnosis. Additionally, it describes various nutraceuticals, along with their sources and the beneficial effects they have on several liver diseases.

**Keywords:** Hepatitis, Hepatocellular carcinoma, Liver cirrhosis, Liver diseases, Non-alcoholic fatty liver disease, Nutraceuticals.

\* Corresponding author Sreejan Manna: Department of Pharmaceutical Technology, University of North Bengal, Darjeeling, West Bengal-734013, India, Department of Pharmaceutical Technology, Brainware University, Barasat, Kolkata, West Bengal-700125, India; E-mail: manna.sreejan@gmail.com

## INTRODUCTION

Nutraceuticals emerged as a potent bridge between nutrition and pharmaceuticals in the constantly evolving health sector. Nutraceutical refers to edibles or edible-derived consumables that combine the terms nutrition and pharmaceuticals. These include edible consumables that provide health and therapeutic benefits, including the prevention and treatment of illnesses [1]. Nutraceuticals have their roots in ancient civilizations, including China, India, and Greece. These cultures utilized traditional herbal medicines and natural chemicals to enhance overall health and treat health issues.

Nevertheless, nutraceuticals have become increasingly popular in recent years due to breakthroughs in scientific research, consumer demand, and the acknowledgment of the limitations of traditional pharmaceutical methods [2]. One of the significant reasons for the rise of nutraceuticals is the growing understanding of the drawbacks of existing medications. While many of the existing medications were made to address specific ailments or symptoms, most have several negative impacts and numerous potential long-term adverse effects. In contrast, nutraceuticals are regarded as more natural and authentic, offering the possibility of addressing the underlying causes of health problems and providing a more comprehensive approach to well-being [3]. The diverse range of nutraceutical goods includes vitamins, minerals, herbs, probiotics, omega-3 fatty acids, antioxidants, and a wide variety of other bioactive components derived from natural sources. These nutraceuticals are thought to have multiple health benefits. These include reducing the risk of developing chronic diseases, boosting the immune system, enhancing brain function, and promoting overall well-being [4]. A key benefit of nutraceuticals is that they can simultaneously impact multiple aspects of health. For instance, a nutraceutical product containing a combination of antioxidants, substances with anti-inflammatory properties, and immune-boosting nutrients can be used to target various health concerns, including cardiovascular health, cognitive function, and the prevention of different diseases [5].

The regulatory environment regarding nutraceuticals varies between countries and regions, reflecting the ongoing debate and changing perception of their classification and safety. Some countries consider nutraceuticals a separate category, meaning they must be labelled and sold according to particular guidelines. At the same time, in certain jurisdictions, they can be regulated as dietary supplements or even pharmaceutical products, depending on the intended purpose and composition [6]. The global nutraceuticals industry has experienced rapid expansion in recent years, despite facing regulatory challenges. This growth is attributed to the increasing demand for natural and authentic health treatments.

In addition, the current surge is fuelled by the growing incidence of chronic diseases, the ageing population, and the heightened interest in preventive medicine [7]. As the nutraceutical industry expands, scientists and healthcare professionals are working to achieve a more thorough scientific understanding of how these substances function as therapeutic agents. This can be achieved through clinical trials, research into synergies among the various components of nutraceuticals, and the development of new nutraceutical treatments tailored to patient-specific characteristics, such as genetic factors and behavior [8].

Nutraceuticals represent a highly promising and rapidly growing area that unites the expertise of nutrition and medicine. The potential use of natural chemicals presents an opportunity to address various health conditions, maintain individuals in good health, and serve as a valuable addition to traditional medical treatment. Over time, nutraceuticals have become increasingly critical to healthcare as scientific knowledge and legal basis advance [9].

The term “nutraceutical,” a fusion of “nutrition” and “pharmaceutical,” is deeply rooted in the rich tradition of humanity. Using natural chemicals and food-based products for curative and preventive care has been a long-standing practice in well-developed traditional health systems [10]. In ancient China, herbal treatments and traditional Chinese medicine have been used for thousands of years. Traditional Chinese Medicine (TCM) practitioners understand the connections between diet, lifestyle, and overall health. They utilized various natural chemicals, including herbs and substances derived from both natural and animal sources, for the treatment of various disease conditions [11]. A similar approach was practised by the Ayurvedic school of medicine in ancient India, which also stressed the importance of balanced nutrition and the use of natural products, including spices, herbs, and plant extracts, for maintaining health and preventing and treating diseases. The Ayurvedic approach to wellness is centred on restoring balance and harmony within the body, mind, and spirit [12]. The ancient Greeks also significantly contributed to studying the therapeutic effects of food and natural chemicals. Hippocrates, commonly referred to as the “father of medicine,” famously declared, “Let food be thy medicine and medicine be thy food,” underlining the underlying connection between nutrition and health [13]. As civilizations progressed, the knowledge of implementing natural cures and food-derived substances strengthened health, including the application of specific preparations such as plant serums or dressings. Over the centuries and millennia, one can observe a cross-flow of expertise and practices acquired and utilized in different cultures and by various schools. This fundamentally reshaped the environment and laid the primary framework that would later give rise to what people would call nutraceuticals nearly 25 centuries later. An earlier mention of the term “nutra” dates back to the late 20<sup>th</sup> century [14]. As individuals became

## CHAPTER 6

# Role of Nutraceuticals in the Treatment of Degenerative Muscle Diseases

**Ranabir Sahu<sup>1,\*</sup>, Ankrita Thapa<sup>1</sup>, Gouhar Jahan Ashraf<sup>1</sup>, Priya Das<sup>1,2</sup>, Partha Pratim Maiti<sup>1</sup>, Paramita Paul<sup>1</sup>, Tarun Kumar Dua<sup>1</sup> and Gouranga Nandi<sup>1</sup>**

<sup>1</sup> *Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India*

<sup>2</sup> *Department of Pharmaceutical Technology, Brainware University, Barasat, Kolkata, West Bengal-700125, India*

**Abstract:** Degenerative muscle diseases are commonly known as neuromuscular disorders where degeneration and progressive weakness are observed in the muscles due to genetic disorders or mutations. Degenerative muscle diseases are caused by a variety of factors, including autoimmune disorders, genetic mutations, metabolic abnormalities, and environmental influences. Among the genetic factors, Duchenne muscular dystrophy, Becker muscular dystrophy, and spinal muscular atrophy are commonly observed, which mostly affect humans of all age groups. Autoimmune responses cause rare inflammatory diseases, polymyositis and dermatomyositis, causing muscle weakness and a distinctive skin rash. There is currently no approved cure for degenerative muscle diseases. Still, treatments such as a combination of corticosteroids and immunosuppressive drugs, physical therapy, and other supportive approaches are commonly used to help muscle function, strength, manage complicated symptoms, and improve quality of life. However, the clinical trial of several drugs (rimeporide and alendronate for Duchenne muscular dystrophy) has been going on. Nutraceuticals, naturally present in food, are dietary supplements that are thought to provide both nutrition and medicinal benefits. Although nutraceuticals cannot correct the genetic abnormalities underlying muscular dystrophy, they can provide additional benefits like maintenance of bone health, muscle hypertrophy, protection against muscle damage, and reduction in inflammation and oxidative stress in muscle tissues. Some nutraceuticals used in neuromuscular disorders are omega-3 fatty acids, vitamins C, D, and E, amino acid derivatives, *etc.* Nutraceuticals and their supplements can regenerate, repair, and remodel the injured tissue by increasing and improving the growth of muscle tissue. The chapter focuses on the current scenario of the different types of degenerative muscle diseases and the role of nutrients in these types of diseases.

---

\* **Corresponding author Ranabir Sahu:** Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India; E-mail: ranabirsahu@nbu.ac.in

**Keywords:** Degenerative muscle diseases, Duchenne muscular dystrophy, Dermatomyositis, Mitochondrial myopathies, Nutraceuticals, Polymyositis.

## INTRODUCTION

The term “degeneration” refers to transitioning from a higher to a lower form and declining moral, physical, or mental attributes [1]. In the eighteenth century, the term “degeneration” was coined to describe the diversity within the human species. A nineteenth-century theory concerning human degeneration began to be connected to progressively horrific incidents both before and during World War II. The term “degeneration,” used to describe the deterioration of cells and structures, fell out of use in genetics and psychiatry after World War II [1, 2]. Recently, degenerative muscle diseases have garnered increasing attention from researchers due to their severity and the challenges involved in finding effective treatments. Besides neurodegenerative diseases, muscle degeneration is widely affecting children and adults [3]. A group of conditions affecting the genetics of the skeletal muscle system came to be known as degenerative muscle diseases [4]. One of the primary causes of degenerative muscle disease is a mutation. Mutations causing substitutions or rearrangements in the mt-DNA can cause inherited disorders affecting the skeletal muscle, heart, brain, kidneys, endocrine system, and hematological functions [3, 4]. Furthermore, several genetic abnormalities, including cycles of muscle necrosis, regeneration, increasing muscle weakness, and degradation, are believed to play a significant role in the pathophysiology of degenerative muscle disease [5]. Though there are currently few treatments available for degenerative muscle diseases, numerous trials have been carried out to date to prevent and block the development of these degenerative muscular diseases. To avoid this degeneration of muscles, consuming food components, plant extracts, and phytochemicals has recently gained interest as a potential therapy option [6]. The entire range of foods with health-promoting and disease-preventing qualities enhanced with certain nutrients, such as vitamins, minerals, herbs, phytochemicals, and probiotics, which are known as functional foods and nutraceuticals. It is possible to obtain nutraceuticals from microbial, animal, and plant sources, including aquatic environments [7]. Researchers have examined the impact of nutraceuticals on muscle degeneration by tracking the molecular processes related to protein turnover, mitochondrial function, and myogenesis [6, 8]. This chapter explores various types of degenerative muscle diseases, their progression, available treatments, and the effects of nutraceuticals on muscle degeneration, providing insight into the underlying molecular pathways.

## **PATHOPHYSIOLOGY OF DEGENERATIVE MUSCLE DISEASES**

### **Configuration of Skeletal Muscle and its Function**

Myofibers are the fundamental building blocks of voluntary skeletal muscle. Long, multinucleate cells produce myofibers. Basically, myofibers form when singly nucleated myoblasts fuse together to create myofibers during development and regeneration (Fig. 1). The endomysial sheath, a connective tissue, surrounds individual myofibers. In contrast, the epimysial connective tissue encases groups of myofibers [3]. At myotendinous junctions, the ends of myofibers produce a specialized attachment for bone insertion that is very force-resistant. Sarcomere chains that run parallel to the length of each myofiber are seen in the highly organized cytoplasm of each myofiber. Each sarcomere has boundaries defined by electron-dense Z bands, and each sarcomere is made up of thick and thin filaments that consist of myosin and actin, respectively [9]. The basement membrane, originally called the extracellular matrix (ECM) layer, envelops myofibers and comprises an external reticular lamina and an internal basal lamina [10]. Moreover, the sarcolemma, which is a specialised plasma membrane, also surrounds myofibers and converts impulses from the motor neurons and other external stimuli into muscle fibres. Together, the sarcolemma and basal lamina form a close alliance that creates a safe niche for satellite cells, which are muscle-regenerating cells. Primarily, these satellite cells are referred to as unipotent adult stem cells, which activate to initiate differentiation and proliferation in response to significant muscle injury [9]. This process produces myoblasts, which can fuse with leftover myofibers or one another to reconstruct the muscle. Furthermore, these satellite cells possess a strong self-renewal capability, which guarantees their survival within the muscle and maintains the muscle's ability to heal after damage [3, 5].

### ***Process of Muscle Degeneration***

Typically, muscle damage is characterized by myofiber necrosis and subsequent regeneration. In this process, only a fragment of a single myofiber may be involved. Necrosis is linked to membrane disruption and cytoplasmic protein leakage, including creatine kinase (CK) and lactate dehydrogenase, which can function as serum indicators of muscle injury. Fig. (2) shows the three different phases of muscle from degeneration or destruction, repair, and remodelling. Sometimes, overlap is observed in these phases. Myofiber necrosis is initiated during the degeneration or destruction phase, where the myofiber sarcolemma is disrupted and damaged due to an influx of extracellular calcium, an increase in myofiber permeability, and the activation of calcium-dependent proteases. The first inflammatory cell, neutrophils, is recruited into the damaged muscle within

## CHAPTER 7

# Role of Nutraceuticals in the Treatment of Degenerative Osteoporosis or Disc Disease

Purnima Ashok<sup>1,#</sup>, Manasa Deepa R.<sup>1,\*</sup>, #, Uma A. Patil<sup>1</sup>, Bharati Arali<sup>1</sup>, Apoorva Dev<sup>1</sup>, A. Madhu<sup>1</sup> and Paramita Paul<sup>2</sup>

<sup>1</sup> East West College of Pharmacy, Bengaluru-560091, Karnataka, India

<sup>2</sup> Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India

**Abstract:** Degenerative disc disease (DDD) is a common condition affecting the intervertebral disc and vertebral bodies, particularly in the lumbar spine, and it is often diagnosed in early to middle age. Osteoblasts and osteoclasts play a crucial role in bone remodeling, which preserves metabolic balance and skeletal integrity. After the old or injured bone has been reabsorbed, new bone material is deposited. Osteocytes regulate bone formation, collagen breakdown, hormonal signals, mechanical strain, and remodeling site and timing. A reduction in bone density may result from imbalances. Commonly, it is associated with various factors, such as genetics, obesity, diabetes, smoking, physical strain, discogenic pain, and gene polymorphisms. Modern medical technologies can help identify encouraging variables to prevent DDD. However, many people do not receive early diagnosis and treatment. Hence, understanding the underlying cellular mechanisms of the inflammatory response can significantly enhance the prevention and treatment of DDD. Additionally, lifestyle modifications like maintaining a healthy diet, exercising regularly, quitting smoking and alcohol, and monitoring DDD-promoting variables can help reduce its incidence. As a consequence of their anti-inflammatory and antioxidant qualities, phytoconstituents produced from plants have drawn interest for their possible therapeutic function in DDD. The significance and utilization of nutraceuticals, pharmaceuticals, and supplements to enhance bone health in DDD patients are highlighted in this chapter.

**Keywords:** Anulus fibrosus, Degenerative disc disease, Flavonoids, Interleukins (IL), MAPK pathways, Nutraceuticals, Polyphenols, Supplements, Tumor necrosis factor (TNF- $\alpha$ ).

\* Corresponding author Manasa Deepa R: East West College of Pharmacy, Bengaluru-560091, Karnataka, India; E-mail: rmanasadeepa@gmail.com

# Contributed equally

## INTRODUCTION

### Degenerative Disc Disease

Sciatica, or sciatic nerve pain, is a neurological discomfort that originates in the back and radiates down the leg and hip, as described for the first time by Domenico Cotugno in 1764 [1]. Schmorl and Andrea further addressed herniations and degenerations and created the contemporary concept of the intervertebral disc [2, 3]. In 1933, Mixter and Barr eventually established the disc's significance in the pathophysiology of lumbosciatic pain and nerve dysfunction. Regardless of gender, degenerative disc disease (DDD) is a frequent problem in early to middle age, and it gets worse with age. Degenerative diseases of the intervertebral disc and accompanying vertebral bodies are more common in the lumbar spine [4]. Degeneration and discogenic pain are connected to several disorders. Largely, DDD is caused by physical and biomechanical stresses on the lumbar spine.

### Role of Intervertebral Disc Components

The intervertebral disc is an inflatable padding that serves as a hinge, ligament, and shock absorber between the vertebrae in the spine. When functioning decorously, it transfers force to the lower vertebrae, acting as a closed hydraulic system, where the “vicious circle” starts to break [5, 6].

The annulus fibrosus (AF) and nucleus pulposus (NP) are the two primary components of the intervertebral disc. The constituents include water, type II collagen, chondrocyte-like cells, and proteoglycan. NP, which is the innermost portion, can withstand severe pressure. AF, due to its increased fibrousness and collagen content, serves as the capsule of the nucleus. As they are avascular, the nucleus and annulus rely on molecular diffusion from blood vessels to get oxygen and nutrients and remove metabolic waste [7, 8].

As degeneration can result from a reduction in the nutritional supply, this idea is essential for understanding the architecture and pathophysiology of the disc. Chondrocytes produce matrix metalloproteinases (MMP) to ensure matrix turnover. Matrix production is aided by growth factors, including insulin-like growth factor, transforming growth factor, and basic fibroblast growth factor. Matrix degradation is controlled by metalloproteinase tissue inhibitors. To maintain the equilibrium between production and breakdown, as well as to reduce matrix synthesis and increase MMP activity, macrophages utilize cytokines, including interferons (IFNs), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), and interleukin-1 (IL-1) [9]. By stimulating nitric oxide production and inducible nitric oxide synthetase, which breaks down matrix components and prevents matrix formation,

TNF- $\alpha$  and IL-1 enhance inflammation [10, 11]. Superoxide, which is secreted by macrophages, has the ability to break down proteoglycans and hyaluronic acid, resulting in deaggregation and halting chondrocyte growth [11]. However, when the pH falls, matrix synthesis progresses more slowly [12].

### **Factors Influencing Degenerative Disc Diseases**

Degenerative disc disease (DDD) is a common aging condition, with only 5-10% experiencing chronic back pain. Age-related trends show a low prevalence under 30 years old, increasing significantly between 30 to 50 years old, with 30-50% showing some disc degeneration on imaging. In people aged 50 to 70 years, 70-90% show evidence, and in people over 70 years, nearly 100% show some signs on imaging [13 - 15].

DDD and its contributing factors in normal aging-related degeneration of the lumbar intervertebral disc occur before degenerative conditions of the lumbar disc, such as lumbar disc herniation and lumbar spinal canal stenosis. Heredity is a significant risk factor for DDD in several investigations. Some people may acquire DDD earlier than others if they have particular gene polymorphisms. A study reports on genetic factors that contribute to the degenerative process of the intervertebral disc, with certain polymorphisms defining its integrity. Mutations in genes coding for matrix molecules alter matrix morphology, affecting disc function and biochemical processes. Degradation enzymes and inflammatory cytokines are influenced by these polymorphisms [16 - 21]. A cohort study in South Africa by Megan Collins and Brendon Pearce reveals such a genetic polymorphism associated with mitochondrial dysfunction and disc degeneration. However, more study on population-specific variations and personalized therapy is needed [22]. Moreover, acquired factors like obesity, diabetes, smoking, physical loading, and bone mineral density have also been associated with DDD [23].

Advanced technology in medical science may assist in the identification of promoting factors as preventive measures in DDD. For example, a study report on lumbosacral arteries, atherosclerosis, and obstruction of the abdominal aorta demonstrates how inadequate blood flow and nourishment to the lumbar intervertebral disc may be a factor in lumbar degenerative disorders. Suspected risk factors for DDD include cardiovascular conditions like diabetes, obesity, and smoking.

DDD prevalence varies globally due to lifestyle, healthcare access, and demographics. Low- and middle-income countries have four times more cases than high-income countries. Nutritional interventions that will assist and ensure food security can be guided by monitoring the diversity and quality of diets. The

## SUBJECT INDEX

### A

ACE inhibitors 37, 38, 201, 203  
 Age-related macular degeneration (AMD)  
     122, 124, 126, 128, 129, 133, 135, 137,  
     138, 139  
 Allicin 7, 19, 35, 91  
 Angiotensin-converting enzyme (ACE) 10,  
     201, 203  
 Anthocyanins 10, 81, 91, 94, 95, 136, 137,  
     139, 175, 179  
 Apigenin 27, 77, 232  
 Arrhythmia 1, 2, 3, 5, 20, 30,  
 Arthritis 61, 62, 63, 65, 67, 70, 71, 73, 74, 75,  
     76, 77, 78, 79, 80, 81, 82, 237  
 Astaxanthin 89, 137, 139, 182, 211  
 Atherosclerosis 1, 17, 18, 20, 23, 26, 27, 31,  
     32, 36, 39, 41, 42, 223

### B

Barberry 12, 14, 23, 28, 159  
 Becker muscular dystrophy (BMD) 195, 202,  
     209  
 Berberine 2, 12, 14, 23, 28, 34, 151, 159, 160,  
     182, 183, 211  
 Bone 61, 63, 65, 66, 67, 68, 72, 75, 76,  
     78, 140, 195, 197, 200, 208, 209, 221,  
     2243, 224, 225, 226, 227, 228, 229, 230,  
     231, 232, 233, 234, 235, 236, 237  
     health 195, 208, 221, 226, 228, 232, 233,  
     234, 235  
     remodeling 65, 66, 221, 224, 225  
     resorption 68, 131, 224, 227, 228, 229, 232,  
     234  
 Boswellia serrata 74, 77, 228  
 Bradycardia 2, 3  
 Brassica 1, 2, 11  
 Bromelain 75, 78, 79  
 Buckwheat 19, 32, 40

### C

Cardiac hypertrophy 14, 20, 21, 22, 23, 39,  
 Cardiomyocytes 12, 14, 16, 20, 21, 22  
 Chondrocytes 61, 66, 74, 77, 222, 226, 227,  
     229  
 Chondroitin sulfate 61, 63, 66, 74, 78, 80,  
     234, 235, 236  
 Chronic inflammation 9, 86, 129, 204  
 Cirrhosis 38, 151, 156, 158, 159, 160, 161,  
     163, 165, 166, 171, 172, 173, 175, 180,  
     183  
 Coenzyme Q10 (CoQ10) 5, 15, 22, 24, 30, 85,  
     87, 175, 178, 208, 209, 210, 211  
 Congestive Heart Failure (CHF) 12, 15, 16  
 Contractility 12, 22, 24, 25  
 Coronary heart disease 11, 13, 31, 32  
 Corticosteroids 79, 195, 201, 204, 205  
 Creatine 41, 197, 208, 209, 210

### D

Degenerative disc disease (DDD) 221, 222,  
     223, 235  
 Dermatomyositis 195, 204, 205, 210  
 Diabetic complications 86, 87, 88, 107  
 Diabetic retinopathy (DR) 89, 122, 124, 127,  
     126, 129, 130, 133, 135, 140  
 Doxorubicin 14, 181, 182  
 Dry eye disease (DED) 124, 133, 135, 138,  
     142  
 Duchenne muscular dystrophy (DMD) 195,  
     201, 202, 208  
 Dyslipidemia 16, 31, 32, 33, 35, 89, 98, 101,  
     107

### E

Eicosapentaenoic acid (EPA) 15, 81, 93, 105,  
     135, 158, 162, 177, 178, 211  
 Electron transport chain (ETC) 5, 22, 131

Emery-Dreifuss muscular dystrophy (EDMD) 201, 203, 209  
 Endothelial dysfunction 9, 10, 19, 30, 32, 89, 129  
 Epigallocatechin-3-gallate (EGCG) 33, 76, 81, 96, 175, 176, 208, 211, 227  
 Extracellular matrix (ECM) 66, 78, 197, 200, 201, 202, 228, 231

**F**

Facioscapulohumeral muscular dystrophy (FSHD) 201, 203, 209  
 Fibrosis 10, 12, 14, 20, 22, 28, 29, 31, 158, 159, 160, 170, 172, 173, 175, 177, 180, 181

**G**

Genistein 18, 77, 97, 135, 228, 229, 231  
 Ginkgo biloba 7, 29, 37, 38, 137, 139, 141  
 Ginseng 151, 160, 163, 180  
 Glucosamine 63, 74, 78, 81, 230, 234, 236  
 Guggul 25, 34, 40

**H**

Hawthorn 24  
 Hepatocellular carcinoma (HCC) 151, 161, 165, 172, 173, 181, 183  
 High-Density Lipoprotein (HDL) 10, 31, 32, 33, 34, 41, 89, 98, 102, 163, 178, 181  
 Hyaluronic acid 68, 74, 78, 80, 223, 236  
 Hyperglycemia 32, 35, 89, 94, 95, 97,  
 Hyperlipidemia 1, 31, 32, 33, 34, 35, 39, 40, 41, 42, 79  
 Hypertrophy 1, 13, 14, 16, 20, 21, 22, 23, 39, 40

**I**

Icariin 229, 231  
 Immune function 134, 136, 181, 210  
 Intervertebral disc 221, 222, 223, 226  
 Ischemia 4, 6, 14, 15, 21, 22, 23, 24, 27, 28, 129, 130, 131, 135

**J**

Joint pain 61, 77, 81, 230, 235, 237

**K**

Kaempferol 97, 100, 227

**L**

L-arginine 15, 17, 65, 208  
 L-carnitine (LC) 6, 85, 87, 175, 177, 180, 209  
 Lactobacillus 92, 101, 102, 103, 104, 135, 161, 163, 179  
 LDL (Low-Density Lipoprotein) 10, 11, 13, 14, 17, 19, 29, 31, 32, 33, 34, 35, 41, 89, 98, 101, 105, 163, 178, 181  
 Lespedeza 18  
 Limb-girdle muscular dystrophy (LGMD) 201, 202, 209  
 Liquorice root 151, 159, 162, 181, 183  
 Lutein 89, 106, 135, 137, 138, 139, 140  
 Lycopene 19, 89, 182

**M**

Macular degeneration 122, 124, 125, 126, 128, 129, 133, 135, 137  
 Malondialdehyde (MDA) 5, 27, 30, 74, 76, 98, 101, 140  
 MAPK (mitogen-activated protein kinase) 29, 66, 74, 75, 96, 221, 225, 229, 231, 232  
 Matrix metalloproteinases (MMPs) 66, 75, 178, 222, 226, 229, 231, 232  
 Melatonin 208, 234, 235  
 Methotrexate 79, 204, 205  
 Methylsulfonylmethane (MSM) 75, 78, 80  
 Metformin 23, 106, 107, 202  
 Muscular Dystrophy 195, 196, 199, 201, 202, 203, 208, 209, 211  
 Myocardial infarction 1, 4, 12, 15, 25, 26, 27, 28, 30, 39, 40, 41  
 Myricetin 96, 97, 100

**N**

N-acetylcysteine (NAC) 161, 163, 176, 181, 182, 208

NAFLD (Non-alcoholic fatty liver disease)  
151, 156, 158, 159, 160, 161, 162, 169,  
170, 173, 175, 177, 178, 179, 180, 181  
Necrosis 25, 27, 197, 198, 200, 201, 202  
Neurodegeneration 124, 128, 132, 133, 134,  
142  
Non-steroidal anti-inflammatory drugs  
(NSAIDs) 63, 79, 80, 81  
Nuts 18, 24, 35, 93, 100, 138, 158, 159, 233,  
235

**O**

Obesity 2, 9, 33, 35, 86, 89, 156, 169, 170,  
221, 223  
Olive oil 19, 34, 93, 96  
Optic nerve 124, 125, 126, 130, 132, 133, 138  
Osteoarthritis (OA) 61, 62, 63, 64, 65, 66, 67,  
68, 69, 73, 74, 75, 76, 77, 78, 80, 81,  
227, 228, 231  
Osteoblasts 221, 224, 227, 228, 229, 230, 232,  
233  
Osteoclastogenesis 228, 229, 231, 232  
Osteoclasts 74, 75, 221, 224, 227, 229, 231,  
232, 233  
Osteoporosis 221, 224, 225, 228, 229, 230,  
231, 232, 235

**P**

Pancreatic 33, 35, 86, 98, 103  
Phenolic compounds 10, 27, 32, 41, 92, 162  
Phytoconstituents 76, 77, 221, 226, 228, 230,  
232  
Plaque 17, 19, 20, 25, 26, 31, 32, 36  
Platelet aggregation 17, 20, 24, 36, 41  
Polymyositis 195, 196, 203, 204, 210  
Proteoglycan 66, 74, 78, 200, 222, 223

**Q**

Quercetin 2, 7, 9, 10, 11, 13, 14, 22, 29, 34,  
39, 40, 41, 76, 97, 100, 211, 227, 231

**R**

Renin-angiotensin-aldosterone system  
(RAAS) 10, 22

Retinal ganglion cells (RGCs) 122, 124, 126,  
128, 130, 131, 133, 135  
Rheumatoid arthritis (RA) 61, 63, 65, 67, 70,  
71, 73, 74, 75, 76, 77, 79, 80

**S**

Saffron 137, 138  
Sarcolemma 197, 199, 200, 202  
Satellite cell 197, 199, 200, 207, 208  
Sciatica 222  
Selenium 138, 208, 209, 210, 211  
Shilajit 63, 75, 78  
Silymarin 151, 157, 158, 162, 175, 177, 180,  
183  
SIRT-1 10, 11, 13, 22, 28, 30  
Spinal Muscular Atrophy (SMA) 195, 206,  
211  
Spirulina 1, 2, 11, 14, 20, 30, 40  
Statins 34, 37, 38  
Steatosis 169, 170, 171, 175, 177  
Stroke 11, 31, 32, 38  
Superoxide dismutase (SOD) 7, 13, 19, 27, 30,  
74, 76, 98, 101, 105, 106, 135, 138, 140,  
163, 180  
Synovitis 69, 72

**T**

Tachycardia 2, 3, 4, 5, 7, 9, 24, 38, 41  
Thiamine 16, 87  
Thrombogenesis 27  
Thrombosis 26, 32, 35  
Total cholesterol (TC) 22, 31, 32, 35, 98, 103,  
178

**V**

Vasodilation 12, 13, 15, 20, 29, 36, 37, 39, 40  
Vasoconstriction 9, 17  
Ventricular arrhythmia 6, 30  
Ventricular fibrillation 5, 7  
Viral hepatitis 156, 161, 163  
Vitamin A 123, 137, 138, 140, 141, 163, 207  
Vitamin B1 (Thiamine) 16, 87

**W**

Warfarin 38, 79, 141, 142

Weight loss 27, 40, 63

## **Z**

Zeaxanthin 89, 90, 135, 137, 138, 139, 140

Zinc 81, 88, 136, 138, 139, 140, 163, 202,  
209, 229, 230, 236



### **Paramita Paul**

---

Paramita Paul is an Assistant Professor in the Department of Pharmaceutical Technology at the University of North Bengal, Darjeeling, India. She completed her B.Pharm., M.Pharm., and Ph.D. degrees at Jadavpur University, Kolkata. She worked as a Senior Research Fellow under the Department of Biotechnology's Twinning Program and received the Government of India's DST Women Scientist-A Award. Dr. Paul has more than 9 years of teaching experience in PCI-approved pharmacy institutions. She has authored fifty-six influential peer-reviewed research and review papers. Additionally, she has authored 4 books and 15 book chapters published by renowned national and international publishers.



### **Ranabir Sahu**

---

Ranabir Sahu is an Assistant Professor in the Department of Pharmaceutical Technology at the University of North Bengal, Darjeeling, India. His research focuses on natural product-based drug discovery, the evaluation of the pharmacological properties of natural products, and nanobiotechnology-based drug delivery systems. Dr. Sahu has received several research grants from various funding agencies. He has published his work in high-impact, peer-reviewed journals and has made significant contributions to the advancement of natural product research and nano-based drug delivery systems.



### **Gouranga Nandi**

---

Gouranga Nandi, PhD, is a faculty member in Pharmaceutics at the University of North Bengal, where he leads innovative research on natural polysaccharide-based novel drug delivery systems. Dr. Nandi has authored more than 100 peer-reviewed articles and has made significant contributions to the advancement of drug delivery science. For his outstanding work, he received a Basic Scientific Research grant from the University Grants Commission of India. He has co-authored two books on pharmaceutical biochemistry and pharmacotherapeutics. In addition to his academic role, Dr. Nandi serves as the Joint Secretary of the Association of Pharmaceutical Teachers of India (APTI), contributing to the advancement of the pharmacy teaching profession in India.



### **Tarun Kumar Dua**

---

Tarun Kumar Dua is an Assistant Professor in the Department of Pharmaceutical Technology at the University of North Bengal, West Bengal, India. He completed his B.Pharm, M.Pharm, and Ph.D. degrees at Jadavpur University, Kolkata. He was awarded the CSIR-SRF Fellowship (2013) by the Council of Scientific and Industrial Research (CSIR), Government of India, and later worked as a Research Associate on a CSIR-funded project at Jadavpur University. He has 5 years of research experience and more than 8 years of teaching experience in AICTE- and PCI-approved pharmacy institutions. Dr. Dua has published over 70 peer-reviewed journal articles and has authored 2 books and 6 book chapters.